G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Rapid Estrogen Signaling Research

Executive Summary. G-1 (CAS 881639-98-1) is a potent, selective agonist for GPR30/GPER1, displaying high affinity (Ki ~11 nM) and negligible binding to classical estrogen receptors ERα/ERβ at micromolar concentrations [APExBIO]. Upon GPR30 activation, G-1 rapidly increases intracellular calcium (EC50 = 2 nM) and triggers PI3K-dependent nuclear PIP3 accumulation, mechanisms implicated in both immune and cardiovascular modulation [Peng Wang et al., 2021]. G-1 inhibits breast cancer cell migration (IC50: 0.7 nM in SKBr3, 1.6 nM in MCF7) and confers cardioprotection in rat heart failure models by modulating β-adrenergic receptor expression. G-1 is a crystalline solid (MW 412.28, C21H18BrNO3), DMSO-soluble (≥41.2 mg/mL), and widely used for dissecting rapid estrogen signaling roles in health and disease.

Biological Rationale

The G protein-coupled estrogen receptor GPR30 (GPER1) mediates rapid, non-genomic estrogen signaling. Unlike nuclear estrogen receptors (ERα, ERβ), GPR30 localizes primarily to the endoplasmic reticulum and plasma membrane [see also]. Estrogen can signal via GPR30 to regulate immune cell function, cardiac physiology, and cancer cell behavior. For example, estradiol-mediated GPR30 activation normalizes splenic CD4+ T lymphocyte proliferation and cytokine production after hemorrhagic shock in rats, a process not reproduced by ERβ agonists [Peng Wang et al., 2021]. This highlights GPR30's distinct physiological roles and the necessity for selective pharmacological tools.

Prior reviews emphasized G-1 as a translational tool for cardiovascular and immune modulation. Here, we provide an updated mechanistic synthesis, clarifying rapid signaling events and experimental boundaries.

Mechanism of Action of G-1 (CAS 881639-98-1), a selective GPR30 agonist

G-1 binds GPR30 (GPER1) with nanomolar affinity (Ki ~11 nM), showing over 100-fold selectivity versus ERα/ERβ [APExBIO]. Upon ligand binding, GPR30 undergoes conformational change, activating intracellular G proteins and initiating several signal transduction pathways:

• Calcium mobilization: G-1 induces rapid elevation of cytosolic Ca²⁺ (EC50 = 2 nM), measured in cell-based assays at 37°C in HBSS buffer.
• PI3K pathway activation: G-1 promotes PI3K-dependent nuclear accumulation of PIP3, detectable within minutes post-treatment in vitro.
• Gene expression modulation: Downstream, GPR30 activation alters expression of genes involved in cell migration, cardiac remodeling, and immune response.

These pathways are functionally distinct from classical ERα/ERβ signaling, which is primarily genomic and slower in onset. G-1's selectivity enables researchers to isolate GPR30 effects from classical estrogen receptor actions [see also].

Evidence & Benchmarks

• G-1 binds GPR30 with Ki ~11 nM, with <1% binding to ERα/ERβ at 10 μM (competitive binding assays, 25°C, pH 7.4) (APExBIO).
• G-1 induces intracellular Ca²⁺ mobilization in GPR30-expressing cells (EC50 = 2 nM), recorded in real-time fluorometric assays (Peng Wang et al., 2021).
• Inhibition of breast cancer cell migration observed at IC50 = 0.7 nM (SKBr3) and 1.6 nM (MCF7) in Boyden chamber assays (APExBIO).
• Chronic G-1 administration in ovariectomized rat heart failure models reduced cardiac fibrosis and normalized β-adrenergic receptor expression (in vivo, female Sprague-Dawley rats, 4 weeks) (Peng Wang et al., 2021).
• G-1 reverses hemorrhagic shock-induced suppression of splenic CD4+ T lymphocyte proliferation via GPR30, not ERβ, in rat ex vivo assays (Peng Wang et al., 2021).
• PI3K pathway activation by G-1 confirmed by increased nuclear PIP3, measured by immunofluorescence and biochemical assays (see summary).

This article extends the mechanistic synthesis found in recent reviews by providing updated, quantitative performance benchmarks and new evidence from immune and cardiac models.

Applications, Limits & Misconceptions

G-1 (CAS 881639-98-1), available from APExBIO, is used to dissect non-classical estrogen signaling in cardiovascular, cancer, and immune research. Key applications include:

• Studying GPR30-mediated rapid signaling in vitro (e.g., calcium flux assays, PI3K activation).
• Evaluating anti-migratory effects in breast cancer models (SKBr3, MCF7).
• Investigating cardioprotective mechanisms in rodent heart failure models.
• Exploring immune modulation post-hemorrhagic shock via normalization of splenic T cell function.

For a comparative discussion on experimental strategies, see G-1: Advancing GPR30-Targeted Research; this article updates those strategies with new dosing and solubility data.

Common Pitfalls or Misconceptions

• G-1 does not activate classical estrogen receptors: At concentrations up to 10 μM, G-1 exhibits negligible activity at ERα and ERβ (APExBIO).
• G-1 is not water or ethanol soluble: Use DMSO for stock solutions; improper solvents reduce assay reliability.
• Long-term storage not recommended: G-1 solutions are stable at -20°C for short periods; avoid repeated freeze-thaw cycles.
• Effects may be model-specific: Cardioprotective and immunomodulatory effects are robust in rodent models but require careful translation to human systems.
• Some estrogenic effects are GPR30-independent: G-1 will not recapitulate ERα/ERβ-driven gene regulation.

Workflow Integration & Parameters

• Preparation: Dissolve G-1 (MW 412.28) in DMSO to >10 mM; use warming and ultrasonic bath to aid dissolution.
• Storage: Aliquot and store at -20°C; avoid prolonged storage and freeze-thaw cycles (APExBIO).
• Working concentration: Effective in vitro at 1–100 nM; in vivo doses should be aligned with rat studies (e.g., daily dosing in heart failure models).
• Controls: Include ERα/ERβ agonists/antagonists to confirm GPR30 specificity.
• Detection: Use rapid readouts (calcium flux, PIP3 translocation), and transcriptomic profiling for downstream effects.

For detailed integration parameters and troubleshooting, refer to the Precision Activation of GPR30 article; our article supplements this with up-to-date solubility and handling guidance.

Conclusion & Outlook

G-1 (CAS 881639-98-1) has become the gold standard for dissecting rapid GPR30-mediated estrogen signaling, given its high selectivity, robust potency, and defined performance parameters. Its applications span cardiovascular, immune, and cancer research, offering mechanistic clarity not achievable with classical ER ligands. APExBIO's G-1 sets a benchmark for reproducibility and translational insight in non-genomic estrogen research. Ongoing studies continue to expand its utility in disease modeling and therapeutic exploration. For detailed product information and ordering, visit the APExBIO G-1 product page.